Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety of Nivestim® in Patients Treated With Neutropenia-inducing Anticancer Chemotherapy in Routine Practice

Trial Profile

Safety of Nivestim® in Patients Treated With Neutropenia-inducing Anticancer Chemotherapy in Routine Practice

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgrastim (Primary) ; Filgrastim (Primary)
  • Indications Febrile neutropenia
  • Focus Adverse reactions
  • Acronyms NEXT
  • Sponsors Hospira
  • Most Recent Events

    • 12 Dec 2015 Results of sub-group analysis (n=463) presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.
    • 14 Jun 2015 Results (subanalysis) presented at the 20th Congress of the European Haematology Association (n = 455).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top